Page last updated: 2024-09-04

olmesartan and osteoprotegerin

olmesartan has been researched along with osteoprotegerin in 2 studies

Compound Research Comparison

Studies (olmesartan)	Trials (olmesartan)	Recent Studies (post-2010) (olmesartan)	Studies (osteoprotegerin)	Trials (osteoprotegerin)	Recent Studies (post-2010) (osteoprotegerin)
841	185	554	5,108	212	2,726

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Araújo, AA; de Castro Brito, GA; do Socorro Costa Feitosa Alves, M; Fernandes de Araújo, R; Lopes de Souza, G; Lourenço, Y; Sabóia Aragão, K; Souza, TO; Xavier de Medeiros, CA	1
Amaya, N; Arakawa, K; Fukuoka, Y; Ishida, K; Lee, JD; Morishita, T; Nakano, A; Tada, H; Uzui, H	1

Trials

1 trial(s) available for olmesartan and osteoprotegerin

Article	Year
Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. Journal of cardiovascular pharmacology and therapeutics, 2014, Volume: 19, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Biomarkers; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Dihydropyridines; Diuretics; Drug Therapy, Combination; Essential Hypertension; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Matrix Metalloproteinase 2; Middle Aged; Osteoprotegerin; Prospective Studies; Tetrazoles	2014

Article

Year

Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.

Journal of cardiovascular pharmacology and therapeutics, 2014, Volume: 19, Issue:3

Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Biomarkers; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Dihydropyridines; Diuretics; Drug Therapy, Combination; Essential Hypertension; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Matrix Metalloproteinase 2; Middle Aged; Osteoprotegerin; Prospective Studies; Tetrazoles

2014

Other Studies

1 other study(ies) available for olmesartan and osteoprotegerin

Article	Year
Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:10 Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Gingiva; Imidazoles; Interleukin-1beta; Male; Malondialdehyde; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Osteoprotegerin; Periodontitis; Peroxidase; RANK Ligand; Rats; Rats, Wistar; Receptor Activator of Nuclear Factor-kappa B; Tetrazoles; Tumor Necrosis Factor-alpha	2013

Article

Year

Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis.

Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:10

Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Gingiva; Imidazoles; Interleukin-1beta; Male; Malondialdehyde; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Osteoprotegerin; Periodontitis; Peroxidase; RANK Ligand; Rats; Rats, Wistar; Receptor Activator of Nuclear Factor-kappa B; Tetrazoles; Tumor Necrosis Factor-alpha

2013